For example, Cre-loxP technology allows precise spatial and temporal control of mutations such as Trp53 deletion and Kras activation, which can mimic the genetic and biological behaviour of human sarcomas such as undifferentiated pleomorphic sarcomas [111, 112]. The gene discussed is KRAS; the disease is undifferentiated pleomorphic sarcoma.